摘要
目的分析正清风痛宁缓释片联合艾瑞昔布治疗类风湿关节炎的临床效果。方法选取2020年6月至2022年6月我院收治的120例类风湿关节炎患者为研究对象,以随机数字表法将其分为常规组(60例,艾瑞昔布)和观察组(60例,正清风痛宁缓释片联合艾瑞昔布)。比较两组的治疗效果。结果观察组的治疗总有效率显著高于常规组(P<0.05)。治疗前,两组的类风湿因子(RF)、C-反应蛋白(CRP)水平及红细胞沉降率(ESR)比较,差异无统计学意义(P>0.05);治疗后,观察组的RF、CRP水平及ESR低于常规组(P<0.05)。治疗前,两组的肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-1β(IL-1β)、降钙素原(PCT)水平比较,差异无统计学意义(P>0.05);治疗后,观察组的TNF-α、IL-6、IL-1β、PCT水平低于常规组(P<0.05)。治疗前,两组的红细胞膜补体受体1型分子(CR1)、膜攻击复合物抑制因子(CD59)及超氧化物歧化酶(SOD)、丙二醛(MDA)水平比较,差异无统计学意义(P>0.05);治疗后,观察组的CR1、CD59及SOD水平高于常规组,MDA水平低于常规组(P<0.05)。治疗后,观察组的Lequesne评分低于常规组,Barthel指数评分高于常规组(P<0.05)。观察组治疗期间的不良反应总发生率显著低于常规组(P<0.05)。结论正清风痛宁缓释片联合艾瑞昔布治疗类风湿关节炎的效果显著。
Objective To analyze the clinical effect of Zhengqing Fengtongning sustained release tablets combined with imrecoxib in the treatment of rheumatoid arthritis.Methods A total of 120 patients with rheumatoid arthritis admitted in our hospital from June 2020 to June 2022 were selected as the research objects.The patients were divided into conventional group(60 cases,imrecoxib)and observation group(60 cases,Zhengqing Fengtongning sustained release tablets combined with imrecoxib)by random number table method.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was significantly higher than that in the conventional group(P<0.05).Before treatment,there were no statistically significant differences in the rheumatoid factor(RF),C-reactive protein(CRP)levels and erythrocyte sedimentation rate(ESR)between the two groups(P>0.05);after treatment,the RF,CRP levels and ESR in the observation group were lower than those in the conventional group(P<0.05).Before treatment,there were no statistically significant differences in the levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),interleukin-1β(IL-1β)and procalcitonin(PCT)between the two groups(P>0.05);after treatment,the levels of TNF-α,IL-6,IL-1βand PCT in the observation group were lower than those in the conventional group(P<0.05).Before treatment,there were no significant differences in the complement receptor type 1(CR1),membrane attack complex inhibitor(CD59),superoxide dismutase(SOD)and malondialdehyde(MDA)levels between the two groups(P>0.05);after treatment,the CR1,CD59 and SOD level in the observation group were higher than those in the conventional group,and the MDA level was lower than that in the conventional group(P<0.05).After treatment,the Lequesne score of the observation group was lower than that of the conventional group,and the Barthel Index score was higher than that of the conventional group(P<0.05).The total incidence of adverse reactions during treatment in the observation group was significantly lower than that in the conventional group(P<0.05).Conclusion Zhengqing Fengtongning sustained release tablets combined with imrecoxib has a significant effect in the treatment of rheumatoid arthritis.
作者
王康
梁栋楼
徐娜
WANG Kang;LIANG Donglou;XU Na(the People's Hospital of Sishui County,Jining 273200;Jining No.1 People's Hospital,Jining 272000,China)
出处
《临床医学研究与实践》
2023年第12期24-27,共4页
Clinical Research and Practice
关键词
类风湿关节炎
艾瑞昔布
正清风痛宁缓释片
rheumatoid arthritis
imrecoxib
Zhengqing Fengtongning sustained release tablets
作者简介
王康(1984—),男,主管药师,学士。研究方向:药事管理、临床药学。;通讯作者:徐娜,E-mail:Xunagirl@126.com.
